It’s Official: CMS Repeals MCIT Rule, Leaves Door Open For Alternatives
Agency also scraps “reasonable and necessary” definition
Executive Summary
Despite industry efforts to save what it viewed as a boon to breakthrough medical technology, US Medicare has repealed the Medical Coverage for Innovative Technologies (MCIT) rule. In a more favorable move for industry, the agency scrapped a controversial qualifying definition for coverage eligibility.
You may also be interested in...
It’s Been Over 1100 Days Since MCIT, Still No TCET In Sight
AdvaMed’s new online clock documents the time since CMS promised to replace MCIT, a program guaranteeing coverage for FDA-cleared breakthrough devices.
Bill Covering Breakthrough Products ‘Step In The Wrong Direction,’ Researchers Say
Researchers from the Brigham and Women’s Hospital and Harvard Medical School argue that the Ensuring Patient Access to Critical Breakthrough Products Act is “a step in the wrong direction.”
Representatives Press CMS On Coverage Of Innovative Devices
Medicare coverage of innovative and life-saving devices, drugs and diagnostics were the focus of a 19 September Congressional hearing during which representatives pressed for swifter and more predictable paths to reimbursement.